Hemp Futures OÜ

In liquidation Registry code 14714275 OÜ Tallinn Registered 30 Apr 2019
Compare

Hemp Futures OÜ is a OÜ based in Tallinn, registry code 14714275, status: in liquidation. Main activity: Manufacture of medicines and other pharmaceutical preparations. According to EMTA, turnover for Q2 2024 was €0 with employees.

Turnover
0 €
State taxes
—
Labour taxes
—
Employees
—

Q2 2024 · data from the Tax and Customs Board (EMTA)

Position in the industry Manufacture of basic pharmaceutical products and pharmaceutical preparations · EMTAK 21

  • Revenue · 2021 56 633 €
    industry median 11 877 € · companies in the industry: 22
  • Net profit margin · 2021 1.3 %
    industry median 1.4 % · companies in the industry: 13

Taxes and turnover

Q1 2022 – Q2 2024
Turnover, € Q2 2024: 0 € · industry median 216 097 € · above 2% of the industry
0100 000200 000300 000400 000Q1 2022 Company: 1 350 € Industry median: 198 773 €Q1·22Q2 2022 Company: 18 285 € Industry median: 209 959 €Q2·22Q3 2022 Company: 0 € Industry median: 117 872 €Q3·22Q4 2022 Company: 0 € Industry median: 311 863 €Q4·22Q1 2023 Company: 46 570 € Industry median: 192 709 €Q1·23Q2 2023 Company: 0 € Industry median: 151 594 €Q2·23Q3 2023 Company: 0 € Industry median: 189 320 €Q3·23Q4 2023 Company: 0 € Industry median: 102 827 €Q4·23Q1 2024 Company: 0 € Industry median: 160 070 €Q1·24Q2 2024 Company: 0 € Industry median: 216 097 €Q2·240100 000200 000300 000400 000Q3 2022 Company: 0 € Industry median: 117 872 €Q4 2022 Company: 0 € Industry median: 311 863 €Q4·22Q1 2023 Company: 46 570 € Industry median: 192 709 €Q2 2023 Company: 0 € Industry median: 151 594 €Q2·23Q3 2023 Company: 0 € Industry median: 189 320 €Q4 2023 Company: 0 € Industry median: 102 827 €Q4·23Q1 2024 Company: 0 € Industry median: 160 070 €Q2 2024 Company: 0 € Industry median: 216 097 €Q2·24
  • Company
  • Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

State taxes, € Q1 2022: 0 €
0.00.00.00.00.00.0Q1 2022 Company: 0 €Q1·22Q2 2022 Company: —Q2·22Q3 2022 Company: —Q3·22Q4 2022 Company: —Q4·22Q1 2023 Company: —Q1·23Q2 2023 Company: —Q2·23Q3 2023 Company: —Q3·23Q4 2023 Company: —Q4·23Q1 2024 Company: —Q1·24Q2 2024 Company: —Q2·24
Figures by quarter
Quarter Turnover, € State taxes, € Labour taxes, € Employees
Q2 2024 — — — —
Q1 2024 — — — —
Q4 2023 — — — —
Q3 2023 — — — —
Q2 2023 — — — —
Q1 2023 46 570 — — —
Q4 2022 — — — —
Q3 2022 — — — —
Q2 2022 18 285 — — —
Q1 2022 1 350 — — —

Financials by year

2019 – 2021
Revenue, € 2021: 56 633 € · +26.0% vs 2020 · industry median 11 877 € · above 60% of the industry
020 00040 00060 0002019 Company: 49 350 € Industry median: 28 809 €20192020 Company: 44 946 € Industry median: 25 207 €20202021 Company: 56 633 € Industry median: 11 877 €2021020 00040 00060 0002019 Company: 49 350 € Industry median: 28 809 €20192020 Company: 44 946 € Industry median: 25 207 €2021 Company: 56 633 € Industry median: 11 877 €2021
  • Company
  • Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit, € 2021: 753 € · −28.4% vs 2020 · industry median 0 € · above 65% of the industry
-15 000-10 000-5 00005 0002019 Company: -13 268 € Industry median: 2 812 €20192020 Company: 1 052 € Industry median: 97 €20202021 Company: 753 € Industry median: 0 €2021-15 000-10 000-5 00005 0002019 Company: -13 268 € Industry median: 2 812 €20192020 Company: 1 052 € Industry median: 97 €2021 Company: 753 € Industry median: 0 €2021
  • Company
  • Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit margin, % 2021: 1.3 % · −1.0 pp vs the year before · industry median 1.4 % · above 45% of the industry
-30-20-10010202019 Company: -26.9 % Industry median: 10.2 %20192020 Company: 2.3 % Industry median: 7.1 %20202021 Company: 1.3 % Industry median: 1.4 %2021-30-20-10010202019 Company: -26.9 % Industry median: 10.2 %20192020 Company: 2.3 % Industry median: 7.1 %2021 Company: 1.3 % Industry median: 1.4 %2021
  • Company
  • Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Assets, € thousand 2021: 179 934 € · +0.4% vs 2020
0501001502002019 Company: 125 382 €20192020 Company: 179 143 €20202021 Company: 179 934 €20210501001502002019 Company: 125 382 €20192020 Company: 179 143 €2021 Company: 179 934 €2021
Equity, € 2021: -13 685 € · −12.0% vs 2020
-15 000-10 000-5 00002019 Company: -13 268 €20192020 Company: -12 216 €20202021 Company: -13 685 €2021-15 000-10 000-5 00002019 Company: -13 268 €20192020 Company: -12 216 €2021 Company: -13 685 €2021
Employees 2021: 0
0102030402019 Company: 0 Industry median: 3420192020 Company: 0 Industry median: 32.520202021 Company: 0 Industry median: —20210102030402019 Company: 0 Industry median: 3420192020 Company: 0 Industry median: 32.52021 Company: 0 Industry median: —2021
  • Company
  • Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Financials by year
Year Revenue, € Net profit, € Labour costs, € Assets, € Equity, € Employees
2021 56 633 753 0 179 934 -13 685 0
2020 44 946 1 052 0 179 143 -12 216 0
2019 49 350 -13 268 0 125 382 -13 268 0

Figures from the company’s own (non-consolidated) balance sheet and income statement. A loss is shown with a minus sign.

Financial ratios for 2021

Net profit margin
1.3 %
Net profit / revenue
Return on assets (ROA)
0.4 %
Net profit / assets
Equity ratio
-7.6 %
Equity / assets
Debt ratio
107.6 %
Liabilities / assets
Current ratio
0.55
Current assets / current liabilities

Annual reports

PDFs from e-Äriregister
Annual reports
Year Period Filed Report Documents
2021 1 Jan 2021 – 31 Dec 2021 6 Apr 2022 Company’s own e-Äriregister
2020 1 Jan 2020 – 31 Dec 2020 6 Apr 2022 Company’s own e-Äriregister
2019 30 Apr 2019 – 31 Dec 2019 4 Mar 2020 Company’s own e-Äriregister

Board

Owners

Beneficial owners

Founders and other persons

Activities (EMTAK)

  • 21201Manufacture of medicines and other pharmaceutical preparations Main

History of changes

What Value Period
Status In liquidation 30 Mar 2023 – now
Status Active 30 Apr 2019 – now

Rulings 10

All rulings (PDF)
Rulings
Number, date Title Deadline State Document
Ä 50118632 / 9
30 Jul 2025
 Amendment entry In force
30 Jul 2025
 PDF
Ä 50118632 / 8
22 Jul 2025
 Amendment entry In force
22 Jul 2025
 PDF
Ä 50118632 / 7
1 Sep 2023
 Amendment entry In force
1 Sep 2023
 PDF
Ä 50118632 / 6
30 Mar 2023
 Termination entry In force
30 Mar 2023
 PDF
Ä 50118632 / M1
4 Apr 2022
 Warning of a fine: annual report not filed 4 May 2022 Deficiencies eliminated
6 Apr 2022
 PDF
Ä 50118632 / 5
16 Nov 2020
 Amendment entry In force
16 Nov 2020
 PDF
Ä 50118632 / 4
13 Nov 2020
 Amendment entry In force
13 Nov 2020
 PDF
Ä 50118632 / 3
9 Oct 2019
 Amendment under Commercial Code § 525 (2) In force
9 Oct 2019
 PDF
Ä 50118632 / 2
13 Jun 2019
 Amendment under Commercial Code § 525 (2) In force
13 Jun 2019
 PDF
Ä 50118632
30 Apr 2019
 First entry In force
30 Apr 2019
 PDF

Sources: e-Äriregister and EMTA. Data updated 1 Nov 2026. Open at the source ↗ · Report an error in the data